Immune checkpoint blockade therapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein 1 (PD1) have shown efficacy in many cancers, like metastatic melanoma and non-small cell lung carcinoma [1,2,3,4]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.